遺伝子治療を目的とする DDS の開発動向
スポンサーリンク
概要
- 論文の詳細を見る
Since the first gene therapy started in USA in 1990, more than 300 clinical trials have been performed. The bases of gene therapy are to transfer a therapeutic gene into target cells by using a gene transfer system (vector) and to treat the disease with physiological activities of gene products for the treatment. The vector used in these processes consists of a gene transfer system and a gene used for the treatment of diseases. This system is associated with the relation of a delivery system and a drug in the Drug Delivery System(DDS) that has hitherto been studied. In fact, many findings obtained in the research and development on DDS have been applied to the recent studies on vectors. At the beginning, gene therapy was expected as “a dream therapy” to give rise to therapeutic effects on any kind of diseases. Nevertheless, only very limited cases in gene therapy gave results indicating overt efficacy in clinical practices, although such studies have been made actively until now. It should be noted that one of the characteristics in protocols of studies in which positive results are obtained is a topical application of vectors. These facts suggest that active targeting at the aimed sites can not be accomplished by systemic administrations of most vectors developed until now, and topical applications have been selected as the most effective procedure to ensure an expression of the gene for treatment at the target sites. It is considered that the key for success in the gene therapy in the future is a further improvement of vectors.
- 日本DDS学会の論文
- 2000-03-10